Tarenflurbil
| Structural formula | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
||||||||||||||||||||||
| General | ||||||||||||||||||||||
| Non-proprietary name | Tarenflurbil | |||||||||||||||||||||
| other names |
|
|||||||||||||||||||||
| Molecular formula | C 15 H 13 FO 2 | |||||||||||||||||||||
| External identifiers / databases | ||||||||||||||||||||||
|
||||||||||||||||||||||
| Drug information | ||||||||||||||||||||||
| Drug class | ||||||||||||||||||||||
| properties | ||||||||||||||||||||||
| Molar mass | 244.26 g · mol -1 | |||||||||||||||||||||
| safety instructions | ||||||||||||||||||||||
|
||||||||||||||||||||||
| As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . | ||||||||||||||||||||||
Tarenflurbil , a non-steroidal anti- inflammatory drug (NSAID), is the eutomer and dextrorotatory enantiomer of flurbiprofen - a racemate .
Tarenflurbil is an active ingredient of the production of beta-amyloid - protein 42 via inhibition of (Abeta) enzyme gamma secretase cuts. When it was taken, a phase III study showed that patients had more Abeta with 38 instead of 42 amino acids. Since the brain can further metabolize these proteins, there are hopes that it can influence the basic process of the formation of plaques specific to Alzheimer's disease. As an effect, the 800 mg per day dosage slowed the gradual deterioration in activities of daily living observed over two years in the mild form of Alzheimer's disease . On the other hand, no significant influence could be seen in the cognitive tests.
See also
Individual evidence
- ↑ a b Data sheet (R) - (-) - 2-Fluoro-α-methyl-4-biphenylacetic acid from Sigma-Aldrich , accessed on April 23, 2011 ( PDF ).
- ↑ Beher D, Clarke EE, Wrigley JD, et al. : Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism . In: J. Biol. Chem. . 279, No. 42, October 2004, pp. 43419-26. doi : 10.1074 / jbc.M404937200 . PMID 15304503 .
- ^ According to the British Alzheimer's Society , news from May 2, 2008.
Web links
- Green et al. 2008 ICAD Presentation Tarenflurbil Phase 3 AD Results (PDF file; 1.25 MB)
- Thomas L. Kukar, Thomas B. Ladd et al: Substrate-targeting γ-secretase modulators. In: Nature 453: 925-929 of June 12, 2008, doi : 10.1038 / nature07055
- Alzheimer's Disease: How an NSAID Could Prevent Plaque Formation. Deutsches Ärzteblatt , news from June 12, 2008
